July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Fenofibrate-loaded biodegradable nanoparticles for treating retinal neovascularization
Author Affiliations & Notes
  • Qingguo Xu
    Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, United States
    Ophthalmology, Virginia Commonwealth University, Richmond, Virginia, United States
  • Fangfang Qiu
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Qian Chen
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Kelu Zhou
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Yan Shao
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Greg Matlock
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Xiang Ma
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Wenjing Wu
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Tuo Meng
    Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, United States
  • Yanhong Du
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Xiang Wang
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Guotao Deng
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Jian-Xing (Jay) Ma
    Physiology, The University of Oklahoma Health Sciences Center, Oklahoma, United States
  • Footnotes
    Commercial Relationships   Qingguo Xu, None; Fangfang Qiu, None; Qian Chen, None; Kelu Zhou, None; Yan Shao, None; Greg Matlock, None; Xiang Ma, None; Wenjing Wu, None; Tuo Meng, None; Yanhong Du, None; Xiang Wang, None; Guotao Deng, None; Jian-Xing (Jay) Ma, None
  • Footnotes
    Support  NIH grants (EY027827, EY018659, EY019309, GM122744), a JDRF grant (2-SRA-2014-147-Q-R), an Oklahoma Center for the Advancement of Science and Technology grant (HR16-041), and a Ralph E. Powe Junior Faculty Enhancement Award.
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6393. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Qingguo Xu, Fangfang Qiu, Qian Chen, Kelu Zhou, Yan Shao, Greg Matlock, Xiang Ma, Wenjing Wu, Tuo Meng, Yanhong Du, Xiang Wang, Guotao Deng, Jian-Xing (Jay) Ma; Fenofibrate-loaded biodegradable nanoparticles for treating retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6393. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Fenofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR). However, the therapeutic effects of fenofibrate through systemic administration are limited due to inefficient drug delivery to the retina. We aimed to explore the long-lasting therapeutic effects of fenofibrate-loaded nanoparticles on both DR and neovascular age-related macular degeneration (AMD).

Methods : Fenofibrate-loaded biodegradable PLGA (34 kDa) nanoparticle (Feno-NP) were prepared, and fully characterized on particle size, surface charge, particle morphology, drug loading, drug release in vitro, and ocular pharmacokinetics in vivo. The efficacy of one single intravitreal injection of Feno-NP on DR and neovascular AMD was investigated using streptozotocin (STZ)-induced diabetic rats, laser-induced choroidal neovascularization (CNV) rats and Vldlr-/- knockout mice. Therapeutic effects of Feno-NP were evaluated by electroretinogram (ERG), retinal vascular leakage, leukostasis, CNV area and retinal levels of VEGF and ICAM-1.

Results : Feno-NP were spherical with the particle size of ~250 nm (Fig 1A). Feno-NP exhibited a drug content of 6 wt% and a sustained drug release up to 60 days (Fig 1B). One intravitreal injection of Feno-NP in rat eyes maintained sustained fenofibric acid drug level in the eye for more than 60 days (Fig 1C). In STZ rats, one intravitreal Feno-NP (30 µg fenofibrate) ameliorated retinal dysfunctions, reduced retinal vascular leakage, inhibited retinal leukostasis, and downregulated the overexpression of VEGF and ICAM-1 at 8 weeks (Fig 1D). One intravitreal Feno-NP (30 µg fenofibrate for rats, and 9 µg fenofibrate for mice) reduced retinal vascular leakage and formation of CNV in both CNV rats at 2 weeks (Fig 1E) and Vldlr-/- mice at 4 weeks (Fig 1F). No toxicity of Feno-NP or Blank-NP to retinal structure and function was detected during a 4-week safety study.

Conclusions : A single intravitreal injection of Feno-NP displayed promising therapeutic potential for the treatment of DR and neovascular AMD with prolonged drug release and potentially reduced injection frequency. Feno-NP were made from all Generally Regarded As Safe (GRAS) materials, facilitating the future translational use.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Fig 1: (A-C) Characterization of Feno-NP; Representative efficacy data of Feno-NP at treating (D) STZ rats, (E) CNV rats, and (F) Vldlr-/- mice.

Fig 1: (A-C) Characterization of Feno-NP; Representative efficacy data of Feno-NP at treating (D) STZ rats, (E) CNV rats, and (F) Vldlr-/- mice.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×